Victoria M Richon

USPTO Granted Patents = 28 (Patent Applications = 12)

CIPO Patents = 2 (Patent Applications = 1)

EPO Patents = 5 (Patent Applications = 5)

Average Co-Inventor Count = 4.4

ph-index = 10

Forward Citations = 326(Granted Patents)

Location History:

New York, NY (US) (2003 - 2008)
Rye, NY (US) (2006 - 2011)
Wellesley, MA (US) (2007 - 2023)

Company Filing History:

12 out of 512

Sloan-kettering Institute for Cancer Research

Merck Hdac Research, LLC

5. 1 out of 832,680

Other

patents

where one patent can have more than one assignee

Years Active: 2003-2023

Loading Chart...

28 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 11633420 - Method of treating leukemia (2023-04-25),

2. 10881680 - Method of treating leukemia (2021-01-05),

3. 9949999 - Inhibitors of human EZH2, and methods of use thereof (2018-04-24),

4. 9597348 - Method of treating leukemia (2017-03-21),

5. 9333217 - Inhibitors of human EZH2, and methods of use thereof (2016-05-10),

6. 9096634 - Substituted purine and 7-deazapurine compounds (2015-08-04),

7. 8895245 - Inhibitors of human EZH2 and methods of use thereof (2014-11-25),

8. 8691507 - Inhibitors of human EZH2 and methods of use thereof (2014-04-08),

9. 8580762 - Substituted purine and 7-deazapurine compounds (2013-11-12),

10. 8101663 - Polymorphs of suberoylanilide hydroxamic acid (2012-01-24),

11. 8067472 - Methods of treating Hodgkin's and non-Hodgkin's lymphoma (2011-11-29),

12. 7879865 - Treatment of cancer of the brain using histone deacetylase inhibitors (2011-02-01),

13. 7851509 - Polymorphs of suberoylanilide hydroxamic acid (2010-12-14),

14. 7816499 - Antibodies that selectively bind HDAC9 (2010-10-19),

15. 7799803 - Hydroxamic acid compounds and methods of use thereof (2010-09-21),

Title: Victoria M. Richon: Innovator in Cancer Treatment

Introduction: Victoria M. Richon, based in Wellesley, MA, has made significant contributions to the field of cancer research, amassing an impressive portfolio of 28 patents. Her pioneering work focuses on innovative methods for treating leukemia and other cancer disorders, exemplifying her commitment to advancing medical science.

Latest Patents: Among her latest patents, Victoria Richon has developed a method of treating leukemia that addresses disorders linked to DOT1L-mediated protein methylation. This invention involves the administration of DOT1L inhibitor compounds and pharmaceutical compositions, offering new hope for patients suffering from cancer.

Career Highlights: Throughout her career, Richon has worked with esteemed organizations such as the Sloan Kettering Institute for Cancer Research and Epizyme, Inc. Her efforts in these institutions have contributed significantly to the advancement of oncology and therapeutic methods for treating complex diseases.

Collaborations: Victoria has collaborated with notable professionals in her field, including Thomas Allen Miller and Paul A Marks. These partnerships reflect her commitment to interdisciplinary research and innovation, further enhancing the impact of her work.

Conclusion: Victoria M. Richon’s extensive patent portfolio and collaborative efforts in cancer research highlight her as an influential inventor and innovator. Her dedication to developing new treatment methods continues to shape the future of cancer therapy.

This text is generated by artificial intelligence and may not be accurate.